Wattle Health Australia


Take5 with OnMarket: Lazarus Karasavvidis, Executive Chairman, answers five questions about the Wattle Health IPO (5:14 minutes).

Fixed Priced IPOType of Offer
28 Jan 17Offer Open
24 Feb 17Pay By
$6-8 millionSize of Offer
$2,000Minimum Bid
JB AdvisoryLead Manager


Wattle Health Australia (ASX: WHA) is an Australian fast moving consumer goods (FMCG) company founded in 2005 and based in Melbourne. WHA is committed to developing, sourcing and marketing high quality, 100% Australian-made consumer food products, currently focusing on dried milk and infant formula products for the domestic Australian as well as Asian export markets.

WHA sources all of its existing commercial products only from Australian manufacturers enabling it have Australian made certification for its products. It currently has 27 product formulations that are anticipated to be able to be commercialised. Of those, 7 food products are currently available in the Australian domestic markets and also export markets. While commercial sales have only just commenced, WHA generated sales of $771,255 for the period 1 July 2016 to 31 October 2016.

In Australia, WHA has an exclusive agreement and has commenced sales with an Australian duty free company, JR Duty Free Pty Ltd to sell the WHA Domestic Infant Formula product range and full cream milk powder in their stores across Australia.

In terms of export markets, WHA has achieved registration, current as at the date of this Prospectus, of its three Export Infant Formulas with China CIQ. China CIQ registration is a requirement export infant formula into China, in all retail and online sales channels. The Chinese CIQ process is complex and it can generally take up to 24 months to secure China CIQ registration for each product.

The Company intends to use the funds raised to increase the sales and marketing budget to expand brand awareness to drive both direct and retail channel sales for WHA’s current commercialised products in the Australian domestic market and with a secondary focus on export markets (leveraging off WHA’s China CIQ registration for its Export Infant Formula range) and provide working capital for a 24 month period.

The expected market capitalisation of the Company is $20.1 to 22.9 million.


Section 734(6) disclosure: The issuer of the securities is Wattle Health Australia Limited ACN 150 759 363. The securities to be issued are ordinary shares. The disclosure document for the offer can be obtained by clicking on the link above. The offers of the securities are made in, or accompanied by, a copy of the disclosure document. Investors should consider the disclosure document in deciding whether to acquire the securities. Anyone who wants to acquire the securities will need to complete the application form that will be in or will accompany the disclosure document (which can be done via the electronic application form which will become available by clicking the bid button above).

The company reserves the right to close the offer early.

Discover investment opportunities here

Tap 'More Info' to get access to free research, all company releases, and invest instantly for shares.

IPO Live

Simble Solutions Ltd ASX: SIS

Simble Solutions Ltd

Simble Solutions Limited (ASX: SIS) is an Australian enterprise Software as a Service (SaaS) company focused on business and resource management. Its energy management solutions are principally catered towards enterprise and SME customers to reduce and manage their energy consumption. The platform is sold via channel partnerships in Australia, UK and NZ.

$6.5-7.5 millionSize of Offer
16 Jan 18Offer Open
09 Feb 18Pay By
IPO Live

Duxton Broadacre Farms Ltd ASX: DBF

Duxton Broadacre Farms Ltd

Update: Firm committments of at Least $15 million have been received.  Offer closing Friday 19th January.

Duxton Broadacre Farms Ltd (ASX: DBF) is expected to be the only ASX listed vehicle of its type in Australia, providing its investors with direct exposure grain production. It provides investors the opportunity to access the Australian grain industry via a portfolio of diversified dry land and irrigated broadacre farms located near Forbes in NSW.


$12-22 millionSize of Offer
29 Nov 17Offer Open
19 Jan 18Pay By
IPO OnMarket Bidding Closed

Rong Yu Pharma. Ltd ASX: RY8

Rong Yu Pharma. Ltd

Applications for the Rong Yu Pharmaceuticals IPO have closed via OnMarket.  The company has extended the offer until 16 March.  

Rong Yu Pharmaceuticals Ltd (ASX RY8) was founded in 2004 and is focussed on the development, manufacture and sale of prescription and OTC pharmaceutical products based on principles of Traditional Chinese Medicine. With revenue of A$71.4 million in FY2017, the Company’s products are sold in 28 Provinces across China via a network of over 300 wholesale distributors.

$15-20 millionSize of Offer
28 Nov 17Offer Open
16 Mar 18Pay By